Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease

被引：0

作者：

Kyohei Isshiki

Takahiro Kamiya

Akifumi Endo

Kentaro Okamoto

Tomoo Osumi

Toshinao Kawai

Katsuhiro Arai

Daisuke Tomizawa

Kazuo Ohtsuka

Masakazu Nagahori

Kohsuke Imai

Motohiro Kato

Hirokazu Kanegane

机构：

[1] National Center for Child Health and Development,Children’s Cancer Center

[2] Tokyo Medical and Dental University Hospital,Department of Pediatrics

[3] Tokyo Medical and Dental University Hospital,Department of Pediatric Surgery

[4] National Center for Child Health and Development,Division of Immunology

[5] National Center for Child Health and Development,Division of Gastroenterology

[6] Tokyo Medical and Dental University Hospital,Department of Gastroenterology and Hepatology

来源：

International Journal of Hematology | 2022年 / 115卷

关键词：

Vedolizumab; GVHD; Children; Gastrointestinal tract; Refractory;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Vedolizumab, an immunosuppressive drug that acts locally on the gastrointestinal tract, is mainly used for the treatment of inflammatory bowel disease, and has been reported to be effective against gastrointestinal acute graft-versus-host disease (GI-aGVHD) in adults. However, there is insufficient evidence for pediatric GI-aGVHD. We used vedolizumab to treat three cases of GI-aGVHD in patients aged 1.5–4.4 years. It was significantly effective in two patients and did not cause serious side effects in any patient. Vedolizumab might be effective and safe for pediatric GI-aGVHD refractory to other treatments, but this must be confirmed in future studies.

引用

页码：590 / 594

页数：4

共 56 条

[1]

Feagan BG(2013)Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 699-710

[2]

Rutgeerts P(2013)Vedolizumab as induction and maintenance therapy for Crohn’s disease N Engl J Med 369 711-721

[3]

Sands BE(2019)Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review Biol Blood Marrow Transplant 25 720-727

[4]

Hanauer S(2019)Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease Bone Marrow Transplant 54 987-993

[5]

Colombel JF(2018)Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn’s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition J Pediat Gastroenterol Nutr 67 257-291

[6]

Sandborn WJ(2021)A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease Bone Marrow Transplant 56 2477-2488

[7]

Sandborn WJ(2021)Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab Gut 67 2-3

[8]

Feagan BG(2020)Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic stem cell transplant recipient Pediatr Blood Cancer 18 1-7

[9]

Rutgeerts P(2021)α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease Pediatr Blood Cancer undefined undefined-undefined

[10]

Hanauer S(2018)Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease BMC Gastroenterol undefined undefined-undefined

← 1 2 3 4 5 6 →